Literature DB >> 14500492

Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Terje E Michaelsen1, Øistein Ihle, Karen Johanne Beckstrøm, Tove K Herstad, Jan Kolberg, E Arne Høiby, Audun Aase.   

Abstract

We studied the in vitro protective activities of human immunoglobulin G1 (IgG1), IgG3, and IgM antibodies against group B meningococci by constructing sets of chimeric mouse-human antibodies (chIgG1, chIgG3, and chIgM, respectively) with identical binding regions against the P1.7 and P1.16 epitopes on PorA. This was done by cloning the V genes of three mouse hybridoma antibodies and subsequently transfecting vectors containing the homologous heavy- and light-chain genes into NSO cells. Cell clones secreting intact human chIgG1, chIgG3, or chIgM antibodies originating from three parent mouse antibodies were isolated. The functional affinities appeared to be similar for all human isotypes and surprisingly also for the pentameric chIgM antibody. chIgG1 exhibited greater serum bactericidal activity (SBA) than chIgG3, while chIgG3 was more efficient in inducing a respiratory burst (RB) associated with opsonophagocytosis than chIgG1 was. On the other hand, chIgM exhibited SBA similar to that of chIgG1, but it exhibited much higher RB activity than chIgG3 and chIgG1 exhibited. The antibodies against the P1.16 epitope were more efficient in terms of SBA than the antibodies against the P1.7 epitope were; thus, 10- to 40-fold-lower concentrations of antibodies against P1.16 than of antibodies against P1.7 were needed to induce SBA. On the other hand, antibodies against these epitopes were equally effective in inducing RB. Our results revealed differences in the functional activities of human chIgG1, chIgG3, and chIgM antibodies against meningococci, which might influence their protective effects against meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500492      PMCID: PMC201080          DOI: 10.1128/IAI.71.10.5714-5723.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Efficient purification of DNA fragments using a protein binding membrane.

Authors:  O Ihle; T E Michaelsen
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

2.  Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B.

Authors:  G Vidarsson; W L van Der Pol; J M van Den Elsen; H Vilé; M Jansen; J Duijs; H C Morton; E Boel; M R Daha; B Corthésy; J G van De Winkel
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

Review 3.  Human antibody effector function.

Authors:  D R Burton; J M Woof
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

4.  Flexibility of human IgG subclasses.

Authors:  K H Roux; L Strelets; T E Michaelsen
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

5.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

6.  Human opsonins to meningococci after vaccination.

Authors:  A Halstensen; B Haneberg; L O Frøholm; V Lehmann; C E Frasch; C O Solberg
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

7.  Virus neutralization by germ-line vs. hypermutated antibodies.

Authors:  U Kalinke; A Oxenius; C Lopez-Macias; R M Zinkernagel; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

8.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM.

Authors:  C T Hughey; J W Brewer; A D Colosia; W F Rosse; R B Corley
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  3 in total

1.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.

Authors:  S Giuntini; D M Granoff; P T Beernink; O Ihle; D Bratlie; T E Michaelsen
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

3.  Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein.

Authors:  Peter T Beernink; Serena Giuntini; Isabella Costa; Alexander H Lucas; Dan M Granoff
Journal:  MBio       Date:  2015-06-23       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.